1. Home
  2. GNTY vs CAPR Comparison

GNTY vs CAPR Comparison

Compare GNTY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNTY
  • CAPR
  • Stock Information
  • Founded
  • GNTY 1913
  • CAPR 2005
  • Country
  • GNTY United States
  • CAPR United States
  • Employees
  • GNTY N/A
  • CAPR N/A
  • Industry
  • GNTY Major Banks
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GNTY Finance
  • CAPR Health Care
  • Exchange
  • GNTY Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • GNTY 450.9M
  • CAPR 525.3M
  • IPO Year
  • GNTY 2017
  • CAPR N/A
  • Fundamental
  • Price
  • GNTY $40.44
  • CAPR $9.74
  • Analyst Decision
  • GNTY Hold
  • CAPR Strong Buy
  • Analyst Count
  • GNTY 3
  • CAPR 7
  • Target Price
  • GNTY $37.33
  • CAPR $39.29
  • AVG Volume (30 Days)
  • GNTY 28.3K
  • CAPR 1.5M
  • Earning Date
  • GNTY 04-21-2025
  • CAPR 03-19-2025
  • Dividend Yield
  • GNTY 2.46%
  • CAPR N/A
  • EPS Growth
  • GNTY 7.03
  • CAPR N/A
  • EPS
  • GNTY 2.74
  • CAPR N/A
  • Revenue
  • GNTY $120,816,000.00
  • CAPR $22,270,465.00
  • Revenue This Year
  • GNTY $8.05
  • CAPR $34.33
  • Revenue Next Year
  • GNTY $4.48
  • CAPR $246.72
  • P/E Ratio
  • GNTY $14.84
  • CAPR N/A
  • Revenue Growth
  • GNTY 1.11
  • CAPR N/A
  • 52 Week Low
  • GNTY $27.01
  • CAPR $3.52
  • 52 Week High
  • GNTY $42.95
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • GNTY 53.05
  • CAPR 34.89
  • Support Level
  • GNTY $39.07
  • CAPR $8.90
  • Resistance Level
  • GNTY $41.39
  • CAPR $13.81
  • Average True Range (ATR)
  • GNTY 1.12
  • CAPR 1.18
  • MACD
  • GNTY 0.01
  • CAPR -0.34
  • Stochastic Oscillator
  • GNTY 59.05
  • CAPR 14.36

About GNTY Guaranty Bancshares Inc.

Guaranty Bancshares Inc is a bank holding company conducting banking activities through its wholly-owned subsidiary. The company provides its customers with a full array of relationship-driven commercial and consumer banking products and services, as well as mortgage, trust, and wealth management products and services that are tailored to meet the needs of small and medium-sized businesses, professionals, and individuals. It also provides other services such as Credit cards, Personal Loans, Business Checking, Treasury Management, and other related services. The company generates its revenue from interest on loans and investments, customer service and loan fees, fees related to the sale of mortgage loans, and trust and wealth management services.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: